Pharmacokinetic/Pharmacodynamic Modelling in??Diabetes Mellitus
- 1 January 2008
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 47 (7) , 417-448
Abstract
Diabetes mellitus is a major health risk in many countries, and the incidence rates are increasing. Diverse therapeutic agents are applied to treat this condition. Since 1960, numerous mathematical models have been developed to describe the glucose-insulin system, analyse data from diagnostic tests and quantify drug effects. This review summarizes the present state-of-the-art in diabetes modelling, with a focus on models describing drug effects, and identifies major strengths and limitations of the published models. For diagnostic purposes, the minimal model has remained the most popular choice for several decades, and numerous extensions have been developed. Use of the minimal model is limited for applications other than diagnostic tests. More mechanistic models that include glucose-insulin feedback in both directions have been applied. The use of biophase distribution models for the description of drug effects is not always appropriate. More recently, the effects of various antidiabetic agents on glucose and insulin have been modelled with indirect response models. Such models provide good curve fits and mechanistic descriptions of the effects of antidiabetic drugs on glucose-insulin homeostasis. These and other types of models were used to describe secondary drug effects on glucose and insulin, and effects on ancillary biomarkers. Modelling of disease progression in diabetes can utilize indirect response models as a disturbance of homeostasis. Future needs are to include glucose-insulin feedback more often, develop mechanistic models for new drug groups, consider dual drug effects on complementary subsystems, and incorporate elements of disease progression.Keywords
This publication has 208 references indexed in Scilit:
- A critical review of mathematical models and data used in diabetologyBioMedical Engineering OnLine, 2006
- Oral Antidiabetic AgentsDrugs, 2005
- Insulin signalling and the regulation of glucose and lipid metabolismNature, 2001
- A Model of β -Cell Mass, Insulin, and Glucose Kinetics: Pathways to DiabetesJournal of Theoretical Biology, 2000
- Pharmacokinetics and Pharmacodynamics of AC137 (25,28,29 Tripro‐Amylin, Human) After Intravenous Bolus and Infusion Doses in Patients with Insulin‐Dependent DiabetesThe Journal of Clinical Pharmacology, 1996
- Receptor‐Based Pharmacokinetic‐Pharmacodynamic Analysis of CorticosteroidsThe Journal of Clinical Pharmacology, 1993
- A kinetic study of chlorpromazine on the hyperglycemic response in rats. II. Effect of chlorpromazine on plasma glucose.Journal of Pharmacobio-Dynamics, 1988
- A kinetic study of chlorpromazine on the hyperglycemic response in rats. I. Effect of chlorpromazine on plasma catecholamines.Journal of Pharmacobio-Dynamics, 1988
- A theoretical model to predict the behavior of glycosylated hemoglobin levelsJournal of Theoretical Biology, 1979
- Kinetics of pharmacologic response I. Proposed relationships between response and drug concentration in the intact animal and manJournal of Theoretical Biology, 1968